Department of Pharmacy, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.
Curr Top Med Chem. 2023;23(10):907-920. doi: 10.2174/1568026623666230427114622.
Due to their unique biological functionality, nanocarriers can be designed to deliver various anti-tumor drugs in vivo, which has a wide and important application prospect in the field of tumor therapy. However, poor biosafety, short blood circulation time, and weak targeting ability still limit the application of nanoparticles in tumor therapy. In recent years, with the development of biomedicine, the biomimetic technology-based biomembrane-mediated drug delivery system is expected to achieve a breakthrough in tumor-targeted therapy due to low immunogenicity, tumor targeting, the adjustability and versatility of intelligent nanocarrier design. This paper mainly reviews the research process of different types of the cell membrane (erythrocyte membrane, cancer cell membrane, bacterial membrane, stem cell membrane, and hybrid membrane)-camouflaged nanoparticles in tumor therapy, as well as the challenges and development prospects in clinical application.
由于其独特的生物学功能，纳米载体可以被设计用于在体内递送各种抗肿瘤药物，这在肿瘤治疗领域具有广泛而重要的应用前景。然而，较差的生物安全性、短的血液循环时间和弱的靶向能力仍然限制了纳米颗粒在肿瘤治疗中的应用。近年来，随着生物医学的发展，基于仿生技术的仿生细胞膜介导的药物传递系统有望在肿瘤靶向治疗方面取得突破，因为其具有低免疫原性、肿瘤靶向性、智能纳米载体设计的可调性和多功能性。本文主要综述了不同类型细胞膜（红细胞膜、癌细胞膜、细菌膜、干细胞膜和杂交膜）伪装的纳米颗粒在肿瘤治疗中的研究进展，以及在临床应用中面临的挑战和发展前景。
